Track market-moving stories before they get noisy

Doximity's CEO and former CFO are named as alleged controlling persons in a securities class action claiming the Company overstated how much its "Newsfeed" product drove revenue growth while allegedly losing market share to competitors.

, /PRNewswire/ -- SueWallSt alerts investors in Doximity, Inc. (NYSE: DOCS) that a securities class action has been filed on behalf of shareholders who purchased common stock between August 8, 2024 and May 13, 2026. Find out if you may be eligible to recover losses. You may also contact Joseph E. Levi, Esq. at [email protected] or (888) SueWallSt.

DOCS declined $5.38 per share, or 23%, closing at $18.01 on May 14, 2026, the last of three Class Period declines identified in the action. The window to apply for lead plaintiff closes on November 16, 2026.

The Named Individual Defendants

The action names Jeffrey Tangney, Doximity's co-founder, Chief Executive Officer, and Chairman of the Board at all relevant times, and Anna Bryson, who served as Chief Financial Officer from May 11, 2021 to April 13, 2026. The complaint identifies these two officers as the executives most principally charged with providing investors an accurate representation of the state of the Company's business, including its financial guidance, and alleges they had unfettered access to internal data and reports, including an internal dashboard.

Sarbanes-Oxley Certification Obligations

Senior officers who sign certifications under Sections 302 and 906 of the Sarbanes-Oxley Act personally attest to the accuracy and completeness of the periodic reports they submit. The practical consequence for shareholders is that accountability under Section 20(a) of the Securities Exchange Act of 1934 can reach individuals, not only the issuer.

Alleged Control Person Liability

Both officers are named under Section 20(a) as alleged controlling persons of Doximity.The pleading alleges they possessed the power and authority to control the contents of the Company's SEC reports, press releases, and presentations to securities analysts and institutional investors.It alleges each received copies of the reports at issue before or shortly after issuance, with the ability and opportunity to prevent their issuance or have them corrected.The action alleges the Chief Executive Officer expressly denied the existence of an e-newsletter product when questioned by an analyst, while the Company allegedly relied on email newsletters and banner ads.Section 20(a) liability is derivative: if the underlying Rule 10b-5 claim succeeds, alleged controlling persons may be held jointly and severally liable."Corporate officers have a duty to ensure their companies' public statements are accurate and complete, and the complaint here alleges that senior Doximity executives had access to internal data that contradicted what shareholders were being told about the Newsfeed and the Company's competitive position." -- Joseph E. Levi, Esq.

Submit your information to learn more or call (888) SueWallSt.

WHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

Frequently Asked Questions About the DOCS Lawsuit

Q: What court was the DOCS class action filed in? A: The case was filed in the United States District Court for the Northern District of California, governed by the Private Securities Litigation Reform Act of 1995.

Q: Who are the defendants named in the DOCS lawsuit? A: The complaint names Doximity, Inc. and a set of individual defendants who held senior positions at the company for all or part of the Class Period, including co-founder, CEO, and Chairman Jeffrey Tangney, CFO Anna Bryson, co-founder and Chief Strategy Officer Nate Gross, and VP of Investor Relations & Revenue Operations, Perry Gold.

Q: What is the DOCS class action lawsuit about? A: A securities class action has been filed against Doximity, Inc. (NYSE: DOCS) alleging materially false and misleading statements between August 8, 2024 and May 13, 2026. Shares fell approximately 23% after the Company disclosed that it missed its already-reduced fiscal 2026 revenue guidance and projected significantly slower growth for fiscal 2027. Investors who purchased shares during the Class Period and suffered losses may be eligible to seek compensation.

Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.

Q: What do DOCS investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible as an absent class member.

Q: What if I already sold my DOCS shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought during the Class Period and sold at a loss may still be eligible to participate.

Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. If there is a settlement or recovery, eligible class members generally submit a claim form to seek their portion.

Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in the securities class action, they are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.

CONTACT:\
Levi & Korsinsky, LLP\
Joseph E. Levi, Esq.\
33 Whitehall Street, 27th Floor\
New York, NY 10004\
[email protected]\
Tel: (888) SueWallSt\
Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

SOURCE SueWallSt.com

SAN DIEGO, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired Doximity, Inc. (NYSE: DOCS) common stock between August 8, 2024 and May 13, 2026, inclusive (the "Class Period"). Doximity is a digital platform for medical professionals that combines health care news, workflow products, and clinician networking.

The complaint alleges that Doximity failed to disclose to investors that it was losing market share to its competitors with more favorable pricing and engagement models.

Investors who suffered significant losses during the Class Period may be eligible to participate in the lawsuit and should contact Robbins LLP for information before the November 16, 2026, lead plaintiff deadline.

Listen to our podcast.

Why Was Doximity Sued?

The complaint alleges that during the Class Period defendants claimed the Company's Newsfeed was its "biggest revenue driver." Specifically, defendants claimed that the Company’s growth was “led by our Newsfeed, which is both our most used and most monetized product” and told investors that the Newsfeed was consistently “reach[ing] new highs,” with “an all-time record of quarterly active prescribers and double-digit growth in the number of articles read or tapped.” In addition, Doximity touted its “deep engagement,” assuring investors that Doximity does not “bombard physicians with ads and messages in hopes of getting lucky” and assured investors that “[Doximity does not] have an e-newsletter product.” In truth, Doximity overstated the impact that its Newsfeed had on its revenue growth, and the Company was losing market share to its competitors with more favorable pricing and engagement models. Additionally, notwithstanding its frequent statements to the contrary, Doximity relied heavily on both banner ads and email newsletters as advertising methods.

Why Did Doximity Stock Drop?

Plaintiff alleges that on November 6, 2025, despite reporting strong second quarter results, Doximity expressed a degree of caution regarding the outlook for ad spending and implied a slowdown in sales growth in the second half of the 2026 fiscal year, which ended on March 31, 2026. As a result of these disclosures, the price of Doximity common stock declined by $8.29 per share, or 13%.

Then, on February 5, 2026, Doximity lowered its revenue guidance for 2026 full fiscal year, which ended on March 31, 2026, and announced that its sales growth had decelerated while its net income had contracted, which will negatively impact its 2026 fiscal fourth quarter. Following these poor financial results, analysts noted that “uncertainty is lingering. This is not widespread, meaning not all pharma[ceutical] clients are holding back” on their advertising spend. Analysts also began to posit that the reason for Doximity’s slowing growth was that the Company was actually losing market share to its competitors. Specifically, an analyst at Evercore noted that older companies, such as Doximity, “are losing share while programmatic, social, and other new formats are gaining share.” As a result of these disclosures, the price of Doximity common stock declined by $5.59 per share, or 17%.

Then, on May 13, 2026, Doximity announced that it missed its already-reduced revenue guidance and projected a significantly slower pace of growth for its 2027 fiscal year, which ends on March 31, 2027. As a result, several analysts downgraded Doximity stock citing issues specific to the Company’s business. For example, Freeman Capital Markets described the news as “a tough pill to swallow” as shares fell to “an all-time low” and Jefferies placed the stock in the “penalty box.” Leerink Partners also put Doximity “in the penalty box” following the “eye-catching” guidance paired with the “shock value” of “[a]ll of the dynamics that lead to the guidance, including market softness, timing of commitments and the spend to ramp its AI products.” RBC Capital Markets noted that Doximity’s stalled net revenue retention suggested an “increasingly competitive market.” As a result of these disclosures, the price of Doximity common stock declined by $5.38 per share, or 23%.

Who May Be Eligible to Participate in the Doximity Class Action?

The lawsuit seeks to represent investors who purchased or otherwise acquired Doximity, Inc. common stock between August 8, 2024 and May 13, 2026. Investors who suffered losses during that period may have legal rights under the federal securities laws.

What Is a Lead Plaintiff?

The lead plaintiff is a court-appointed investor who represents the interests of all class members throughout the litigation. Stockholders who wish to lead the class action should contact Robbins LLP before the November 16, 2026, lead plaintiff deadline.

Serving as lead plaintiff is not required to share in any potential recovery. Investors who do not seek appointment may remain absent class members if the case proceeds and later resolves successfully.

Does It Cost Anything to Participate?

No. Robbins LLP represents investors on a contingency fee basis.

Why Robbins LLP?

A recognized leader in shareholder rights litigation, Robbins LLP represents investors in securities fraud and shareholder derivative litigation. We have helped restore more than $2 billion in value to shareholders and secured some of the largest recoveries in shareholder derivative litigation history.

"Companies have an obligation to provide investors with complete and accurate information so that markets can function fairly and efficiently," said Brian J. Robbins, Founding Partner of Robbins LLP.

To be notified if a class action against Doximity, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Contact Robbins LLP

Investors seeking additional information about the Doximity, Inc. securities class action may contact Robbins LLP by submitting an inquiry, emailing attorney Aaron Dumas, Jr., or calling (800) 350-6003.

Attorney Advertising. Past results do not guarantee a similar outcome.

Bath & Body Works is benefiting from strong international demand, higher product shipments and store expansion as it works to restore sustainable growth.

, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AST SpaceMobile, Inc. ("AST" or the "Company") (NASDAQ: ASTS) and certain officers. The class action, filed in the United States District Court for the Western District of Texas, Midland-Odessa Division, and docketed under 26-cv-00378, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired AST securities between March 4, 2025 and July 15, 2026, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are an investor who purchased or otherwise acquired AST securities during the Class Period, you have until November 13, 2026 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.  

[Click here for information about joining the class action]

AST, together with its subsidiaries, designs and develops the constellation of BlueBird satellites in the United States ("U.S.").  The Company provides a cellular broadband network in space for direct access by smartphones for commercial use and other applications, as well as for government use.  In addition, its SpaceMobile service provides cellular broadband services to end-users who are out of terrestrial cellular coverage.

At all relevant times, Defendants touted AST's purportedly unique competitive advantages and leadership position in the satellite direct-to-cellular ("D2C") market.  In particular, throughout the Class Period, Defendants touted AST's business and financial prospects as purportedly the only established space-based cellular broadband network for mobile phones.

Defendants' assurances regarding AST's purportedly durable competitive position in the satellite D2C market came into question in September 2025, when American telecommunications company EchoStar Corporation ("EchoStar") announced that it had entered into a definitive agreement with SpaceX, an American aerospace manufacturer and space transportation company, to sell its AWS-4 and H-block spectrum licenses (the "EchoStar Transaction").  In connection with the EchoStar Transaction, SpaceX and EchoStar agreed to enter into a long-term commercial agreement, enabling EchoStar's Boost Mobile subscribers—through its cloud-native 5G core—to access SpaceX's next generation D2C service provided by its telecommunications subsidiary Starlink Services, LLC ("Starlink").

SpaceX commands a dominant position in the global aerospace and orbital launch industry, with the ability to produce and launch numerous satellites at scale.  Its subsidiary Starlink provides a broadband internet satellite constellation that accounts for roughly 54% of all active satellites in Earth's orbit, with approximately 9,821 Starlink satellites currently active in low Earth orbit.  Viewed in combination with its considerable resources, SpaceX's entry into the satellite D2C market was potentially a threat to AST's commercial aspirations.

Following the EchoStar Transaction, however, Defendants continued to assure investors and the market that AST remained in a competitive class of its own, with the Company poised to realize significant revenues and profits in the near-term.  Likewise, Defendants continuously represented that AST's capital and liquidity position was sufficient to meet its strategic and business goals at all relevant times, notwithstanding the heightened competitive pressures it faced following the EchoStar Transaction.

The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) AST's increasing capital requirements were likely to increase the Company's debt load and share dilution with greater frequency and at greater scale than Defendants had signaled to investors; (ii) accordingly, Defendants had overstated the sufficiency of AST's capital and liquidity position to achieve its strategic and business goals; (iii) Defendants likewise overstated the durability of AST's competitive position in the satellite D2C market; (iv) even following the EchoStar Transaction, Defendants continued overstating AST's competitive position in the satellite D2C market; (v) AST was experiencing slow user adoption in the U.S. and Japan; (vi) the foregoing was likely to have a significant negative impact on the Company's business and financial prospects; and (vii) as a result, Defendants' public statements were materially false and misleading at all relevant times.

The truth began to emerge on September 8, 2025, when UBS issued a report downgrading AST to a "Neutral" from "Buy" recommendation, as well as cutting its price target on the Company to $43.00 from $62.00, mainly citing heightened competitive pressures related to the EchoStar Transaction, which "fortifies [Starlink's] position in the space to cellular market and increases risk for AST[] as it drives utilization on its nascent constellation[.]"

Following the release of UBS's report, AST's Class A common stock price fell $3.86 per share, or 9.47%, to close at $36.91 per share on September 9, 2025.

On October 21, 2025, AST issued a press release "announc[ing] its intent to offer . . . $850.0 million aggregate principal amount of convertible senior notes due 2036 (the 'Notes') in a private offering", and that it "intends to grant the initial purchasers of the Notes . . . an option to purchase . . . up to an additional $150.0 million aggregate principal amount of Notes."  The press release disclosed that AST would use the proceeds from this offering "for general corporate purposes, including without limitation funding the deployment of AST SpaceMobile's worldwide constellation of satellites in anticipation of adding incremental strategic markets for its SpaceMobile Service."  (Emphasis added.)

Later the same day, AST issued another press release "announc[ing] the pricing of $1.0 billion aggregate principal amount of convertible senior notes due 2036 (the 'Notes') in a private offering", noting that "[t]he size of the offering has been increased from the previously announced $850.0 million principal amount of Notes", while reiterating the same intended use for the net proceeds from the offering.

Following these disclosures, AST's Class A common stock price fell $7.26 per share, or 9.24%, to close at $71.35 per share on October 22, 2025.

On January 6, 2026, Scotiabank issued a report downgrading AST to a "Sell" recommendation, as well as its rating to "Sector Underperform" from "Sector Perform", citing, inter alia, significant competition from Starlink and "[e]vidence of slow user adoption in the U.S. and Japan[.]"

Following the release of Scotiabank's report, AST's Class A common stock price fell $11.76 per share, or 12.06%, to close at $85.73 per share on January 7, 2026.

On February 11, 2026, AST issued a press release "announc[ing] its intent to offer . . . $1.0 billion aggregate principal amount of convertible senior notes due 2036 (the 'Notes') in a private offering", and that it "intends to grant the initial purchasers of the Notes . . . an option to purchase . . . up to an additional $150.0 million aggregate principal amount of Notes."  The press release disclosed that AST intended to use the proceeds from the offering "for general corporate purposes, including without limitation, accelerating the deployment of our controlled spectrum bands on a global basis, monetizing the capabilities of our proprietary technology to capture the evolving commercial opportunities related to artificial intelligence, enhancing investment in government space opportunities in the U.S., reducing higher interest debt, and pursuing opportunistic investments to accelerate our SpaceMobile Service and capabilities."   (Emphasis added.)

The next day, AST issued another press release announcing the pricing of the foregoing offering at "an initial conversion price of approximately $116.30 per share of AST SpaceMobile's Class A common stock, which represents a premium of approximately 20% to the last reported sale price of AST SpaceMobile's Class A common stock on February 11, 2026."

Following these disclosures, AST's Class A common stock price fell $14.70 per share, or 15.17%, to close at $82.22 per share on February 12, 2026. 

Then, on July 15, 2026, AST issued a press release "announc[ing] its intent to offer" yet another "$1.0 billion aggregate principal amount of convertible senior notes due 2034 (the 'Notes') in a private offering", and that it "intends to grant the initial purchasers of the Notes . . . an option to purchase . . . up to an additional $150 million aggregate principal amount of Notes."  The press release disclosed that AST intended to use the proceeds from the offering to, inter alia, "pursue an expanding universe of growth initiatives and secure additional access to orbit for its space-based cellular broadband network, including partnerships and/or acquisitions to further vertically integrate its business and mitigate risks associated with third-party launch providers."   (Emphasis added.)  The press release further disclosed that the Company "currently does not have any understandings or agreements with respect to any such strategic transactions."  (Emphasis added.)

Later the same day, AST issued another press release announcing the pricing of the foregoing offering.  Specifically, "$1.0 billion 1.625% convertible senior notes due 2034 . . . [at] an initial conversion price of approximately $79.57 per share of AST SpaceMobile's Class A common stock, which represents a premium of approximately 20.0% over the last reported sale price of AST SpaceMobile's Class A common stock on July 15, 2026", as well as "[c]apped call transactions . . . [at] an initial cap price of $149.20 per share of AST SpaceMobile's Class A common stock, which represents a premium of 125.0% over the last reported sale price of AST SpaceMobile's Class A common stock on July 15, 2026."

Following the foregoing disclosures, AST's Class A common stock price fell $11.30 per share, or 17.04%, to close at $55.01 per share on July 16, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com. 

Attorney advertising.  Prior results do not guarantee similar outcomes.  

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

Nu Holdings Ltd. (NU - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Over the past month, shares of this company have returned -5.5%, compared to the Zacks S&P 500 composite's +0.9% change. During this period, the Zacks Banks - Foreign industry, which Nu falls in, has lost 6.4%. The key question now is: What could be the stock's future direction?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Revisions to Earnings EstimatesRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

Nu is expected to post earnings of $0.23 per share for the current quarter, representing a year-over-year change of +35.3%. Over the last 30 days, the Zacks Consensus Estimate remained unchanged.

The consensus earnings estimate of $0.86 for the current fiscal year indicates a year-over-year change of +38.7%. This estimate has changed -0.2% over the last 30 days.

For the next fiscal year, the consensus earnings estimate of $1.16 indicates a change of +34.9% from what Nu is expected to report a year ago. Over the past month, the estimate has changed -0.3%.

Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Nu is rated Zacks Rank #3 (Hold).

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Projected Revenue GrowthWhile earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.

For Nu , the consensus sales estimate for the current quarter of $5.73 billion indicates a year-over-year change of +37.3%. For the current and next fiscal years, $22.51 billion and $27.93 billion estimates indicate +42.7% and +24.1% changes, respectively.

Last Reported Results and Surprise HistoryNu reported revenues of $5.51 billion in the last reported quarter, representing a year-over-year change of +50.3%. EPS of $0.22 for the same period compares with $0.14 a year ago.

Compared to the Zacks Consensus Estimate of $5.45 billion, the reported revenues represent a surprise of +1.08%. The EPS surprise was +10%.

Over the last four quarters, Nu surpassed consensus EPS estimates three times. The company topped consensus revenue estimates three times over this period.

ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.

While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.

The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Nu is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Nu . However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

NZDUSD recovered from lows around 0.5565 to 0.5709 as expectations of an RBNZ rate hike and falling U.S. Treasury yields supported buyers. However, repeated attempts to clear resistance around 0.5710 failed before the central bank’s surprise decision triggered a sharp reversal.

On Wednesday, NZDUSD fell from around 0.5709 towards 0.5580 after the RBNZ voted 4-3 to leave interest rates unchanged at 2.75%, disappointing expectations of a 25-basis-point increase.

The selling extended across NZD crosses. AUDNZD gained more than 250 pips, while EUR/NZD and GBPNZD each advanced more than 300 pips during the session.

NZDUSD subsequently recovered towards 0.5640, where sellers returned. Price has since retreated towards 0.5617, although Wednesday evening’s Fed decision offered limited additional downside momentum.

A divided Fed hold offers limited Dollar supportThe Fed left its policy rate unchanged in a 10–2 vote, with two members preferring a 25-bps.  

Despite those hawkish dissents, markets interpreted Chair Kevin Warsh’s press conference as dovish, reducing expectations for subsequent tightening. Falling Treasury yields have consequently limited the dollar’s ability to extend its gains against the New Zealand dollar.

The distinction matters: the Fed retained its concerns about inflation, but the market’s response reflected a softer interpretation of the future policy path.

The fundamental outlook remains mixedThe RBNZ’s unexpected pause weakened the immediate case for NZD buyers, but the bank left further tightening possible. That makes it difficult to treat the decision as confirmation of sustained monetary-policy support for sellers.

The U.S. side is similarly complicated. Two Fed members supported an immediate hike, yet declining yields suggest traders have not interpreted the meeting as a reason to price a substantially more aggressive tightening cycle.

Further movement in NZD/USD will depend partly on whether the RBNZ disappointment continues to outweigh the loss of dollar support from lower yields. Upcoming U.S. inflation data could help resolve that tension by changing expectations for the Fed’s next move.

NZD/USD technical outlook: 0.5640 and 0.5580 frame the next moveResistance around 0.5640 is the first level buyers need to reclaim. A sustained break above it would strengthen the recovery case and bring 0.5700–0.5710 back into focus.

For sellers, Wednesday’s low around 0.5580 remains the key test. A sustained break below that level would strengthen the bearish structure and expose the earlier low around 0.5565.

Mobileye Global (MBLY - Free Report) reported $492 million in revenue for the quarter ended September 2026, representing a year-over-year decline of 2.4%. EPS of $0.11 for the same period compares to $0.09 a year ago.

The reported revenue represents a surprise of +3.83% over the Zacks Consensus Estimate of $473.84 million. With the consensus EPS estimate being $0.10, the EPS surprise was +10%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Mobileye performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Number of systems shipped: 9.5 million versus 9.21 million estimated by five analysts on average.Average system price: $49.10 versus the four-analyst average estimate of $48.98.EyeQ and SuperVision revenue: $468 million compared to the $446.61 million average estimate based on four analysts.View all Key Company Metrics for Mobileye here>>>

Shares of Mobileye have returned -4.5% over the past month versus the Zacks S&P 500 composite's +0.9% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Besides Wall Street's top-and-bottom-line estimates for MPLX LP (MPLX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2026.

Key Takeaways Viking's injectable VANQUISH trials remain on track, while its oral VK2735 Phase III program is underway.VK2735 retained up to 97% of initial weight loss with biweekly dosing and up to 90% with monthly dosing.VKTX ended September with $960 million in cash and investments after raising about $550M in net proceeds.
Viking Therapeutics, Inc. (VKTX - Free Report) emphasized progress across its obesity pipeline during its third-quarter 2026 earnings call, highlighting the advancement of four Phase III trials evaluating injectable and oral VK2735.

Management also discussed encouraging weight-maintenance data, expanded commercial preparations and a strengthened balance sheet. Analyst questions focused on clinical differentiation, regulatory opportunities and the economics of oral dosing.

Viking Advances Injectable VK2735 TrialsPresident and CEO Brian Lian confirmed that both Phase III VANQUISH trials remain on track, with enrollment completed across studies evaluating patients with obesity and those with obesity and type 2 diabetes.

The trials assess weekly injectable VK2735 over 78 weeks. Management expects both studies to finish in 2027, with extension studies beginning in the first quarter.

Responding to a UBS analyst, Lian cautioned against cross-trial comparisons with competing treatments. He expressed confidence in VK2735's clinical profile but declined to forecast Phase III efficacy.

VKTX Launches Oral Phase III ProgramViking initiated its SUNRISE Phase III program in October, expanding VK2735 development into daily oral treatment. Both studies will assess efficacy and safety over 68 weeks.

Lian explained that the selected doses of 27.5 mg, 35 mg and 55 mg reflect efforts to reduce tablet burden while maintaining commercially attractive gross margins.

In response to Leerink Partners, he clarified that dose escalation follows four-week intervals. Management believes oral treatment could broaden patient options alongside injectable therapy.

Viking Highlights Flexible Maintenance DosingThe VK2735 maintenance study emerged as a central discussion topic. Participants retained 83-97% of initial weight loss with every-other-week injections and 82-90% with monthly administration.

Lian emphasized that gastrointestinal adverse events during maintenance were comparable to placebo. He attributed the encouraging profile to VK2735's pharmacokinetic characteristics.
Part 2 will examine transitions from weekly injections to daily oral therapy and additional injectable schedules.

Management expects results in 2027, although Lian acknowledged uncertainty around oral maintenance efficacy because of differences in drug exposure.

VKTX Addresses Regulatory and Commercial PlansA JPMorgan analyst questioned whether maintenance findings could support differentiated FDA labeling. Lian indicated that VANQUISH extension data could support such language, subject to regulatory review.

Responding to Oppenheimer and Laidlaw analysts, he clarified that maintenance evidence would more probably support a supplemental filing rather than the initial application. The final regulatory approach remains undecided.

Viking is simultaneously expanding commercial capabilities. Lian described established leadership across market access, medical affairs and health economics, alongside recent hiring in manufacturing, supply chain and compliance. He indicated that potential commercialization remains approximately two and a half years away.

Viking Expands Its Amylin Development StrategyBeyond VK2735, Viking expects to complete the Phase I single ascending dose study of VK3019, its dual amylin and calcitonin receptor agonist, by year-end.

A four-week multiple ascending dose study is planned for the first quarter of 2027. Lian emphasized tolerability, pharmacokinetics and weight-loss trajectories as important evaluation criteria.

During discussions with Jefferies, management identified potential applications both as standalone therapy and in combination with VK2735. Lian emphasized that clinical evidence will determine subsequent development decisions.

VKTX Strengthens Funding for Clinical ExpansionChief financial officer Gregory Zante reported third-quarter research and development expenses of $166.8 million compared with $90 million a year earlier, reflecting expanding clinical and manufacturing activities.

Viking posted a loss of $1.55 per share, wider than the Zacks Consensus Estimate of a $1.00 loss. Its quarterly net loss increased to $183.2 million from $90.8 million.

Following financing transactions generating approximately $550 million in net proceeds, Viking ended September with $960 million in cash and investments. Zante indicated average quarterly cash usage of approximately $100 million going forward, with spending varying between quarters.

Viking Maintains Focus on ExecutionManagement's commentary emphasized advancing late-stage clinical studies while developing differentiated dosing options and preparing for commercialization.

The call also highlighted ongoing regulatory uncertainties surrounding maintenance labeling and the importance of forthcoming clinical results in determining VK2735's commercial positioning.

What Zacks Rank and Style Scores Indicate for VKTXVKTX currently carries a Zacks Rank #2 (Buy), indicating favorable near-term prospects based on earnings estimate revisions. However, its Value Score of D, Growth Score of F and Momentum Score of C reflect less favorable characteristics across these investment styles. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Its VGM Score of F also indicates weak combined value, growth and momentum characteristics, limiting the support provided by Style Scores despite the favorable rank. The Zacks Rank remains subject to change as analysts revise earnings estimates following the reported results.

LOS ANGELES, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Hims & Hers Health, Inc. (“Hims & Hers” or “the Company”) (NYSE: HIMS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of HIMS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD: August 4, 2025 to July 29, 2026

DEADLINE: November 2, 2026

If you are a shareholder who suffered a loss, click here to participate.

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Hims & Hers provided customer health data to third-party advertising platforms. The Company’s treatment practices were likely to result in heightened regulatory scrutiny. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Hims & Hers, investors suffered damages.

We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

Join the case to recover your losses

WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.        

CONTACT:

Schall, Brown & Schwartz LLP
Brian Schall, Esq.,
Andrew Brown, Esq.,
David Schwartz, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

SOURCE:

 Schall, Brown & Schwartz LLP

SAN DIEGO, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Hims & Hers Health, Inc. (NYSE: HIMS) securities between August 4, 2025 and July 29, 2026, inclusive (the "Class Period"). Hims operates a health and wellness platform that connects consumers to licensed healthcare professionals.

The complaint alleges that Hims shared consumers' sensitive health information with advertising platforms while representing that its services were private and secure, and engaged in deceptive billing practices.

Investors who suffered significant losses during the Class Period may be eligible to participate in the lawsuit and should contact Robbins LLP for information prior to the November 2, 2026 lead plaintiff deadline.

Why Was Hims & Hers Sued?

According to the complaint, defendants failed to disclose to investors that:

(1) the Company shared consumers’ health information with third-party advertising platforms;
(2) the Company charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is “right for them;”
(3) the foregoing conduct subjected the Company to regulatory scrutiny;
(4) as a result, the Company was reasonably likely to incur fees and penalties; and
(5) as a result of the foregoing, defendants’ positive statements about the Company’s business,
operations, and prospects were materially misleading and/or lacked a reasonable basis.

Why Did HIMS Stock Drop?

Plaintiff alleges that on July 29, 2026, during market hours, the Federal Trade Commission (“FTC”) announced it had filed a lawsuit against Hims “alleging that the telehealth provider shared consumers’ sensitive health information about medical conditions with third-party advertising platforms despite claiming its services maintain consumers’ privacy and deceives users about its billing and cancellation practices.”

According to the FTC’s complaint, Hims engages in other deceptive advertising practices, including failing to “clearly disclose that it charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is ‘right for them.’” The complaint further alleges that, contrary to its promises that the platform is “100% online, private, and secure,” Hims “shared sensitive health information with third-party advertising companies and
platforms . . . such as Meta Platforms, Inc. (‘Meta’) and Snap Inc. (‘Snap’).”

On this news, shares of Hims declined $4.32, or 14.73%, to close at $25.00 on July 29, 2026.

Who May Be Eligible to Participate in the Hims & Hers Class Action?

The lawsuit seeks to represent investors who purchased or otherwise acquired Hims securities between August 4, 2025 and July 29, 2026. Investors who suffered losses during that period may have legal rights under the federal securities laws.

What Is a Lead Plaintiff?

The lead plaintiff is a court-appointed investor who represents the interests of all class members throughout the litigation. Shareholders who wish to lead the case should contact Robbins LLP prior to the November 2, 2026 lead plaintiff deadline.

Serving as lead plaintiff is not required to share in any potential recovery. Investors who do not seek appointment may remain absent class members if the case proceeds and later resolves successfully.

Does It Cost Anything to Participate?

No. Robbins LLP represents investors on a contingency fee basis.

Listen to our podcast.

Why Robbins LLP?

A recognized leader in shareholder rights litigation, Robbins LLP has helped restore more than $2 billion in value to shareholders and secured some of the largest recoveries in shareholder derivative litigation history.

"Companies have an obligation to provide investors with complete and accurate information so that markets can function fairly and efficiently," said Brian J. Robbins, Founding Partner of Robbins LLP.

To be notified if a class action against Hims & Hers Health, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Contact Robbins LLP
Investors seeking additional information about the Hims & Hers Health, Inc. securities class action may contact Robbins LLP by submitting an inquiry, emailing attorney Aaron Dumas, Jr., or calling (800) 350-6003.

Attorney Advertising. Past results do not guarantee a similar outcome.

Although the revenue and EPS for Restaurant Brands (QSR) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Sweetgreen (SG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Key Takeaways ICHR expects Q3 revenues of $315-$345 million, with the midpoint implying 12% sequential growth. ICHR targets Q3 gross margins of 14.5-15.5% as manufacturing realignment boosts efficiency.ICHR expects proprietary content to reach 30% by Q3-end and 35% by the end of 2026.
Ichor Holdings, Ltd. (ICHR - Free Report) is scheduled to report its third-quarter 2026 results on Nov. 2, 2026.

For the third quarter of 2026, Ichor expects revenues between $315 million and $345 million. The midpoint implies sequential growth of 12% and year-over-year growth of 38%. The Zacks Consensus Estimate for second-quarter revenues is pegged at $300.2 million, suggesting a year-over-year increase of 38%.

For the third quarter of 2026, Ichor expects non-GAAP earnings to be in the range of 40-50 cents per share. The Zacks Consensus Estimate for ICHR’s second-quarter 2026 earnings is pegged at 45 cents per share, implying a significant year-over-year increase of 542.9%. ICHR reported earnings of 7 cents per share in the year-ago quarter.

ICHR’s earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters while missing once, the average surprise being 25.02%.

Let’s see how things have shaped up for this announcement.

Key Factors to Note for Ichor Holdings' Q3 EarningsIchor Holdings' third-quarter performance is expected to have benefited from strong demand from wafer fabrication equipment customers, supported by rising investments in AI infrastructure and advanced semiconductor manufacturing. The company also expects second-half 2026 revenue volumes to be at least 25% higher than the first half, supported by demand for advanced etch and deposition equipment.

The company is expected to have benefited from increasing adoption of gate-all-around architectures, advanced memory and leading-edge process technologies, which require more complex semiconductor manufacturing processes. Rising investments in AI infrastructure are supporting demand for etch and deposition equipment, which, in turn, is expected to have driven demand for Ichor's fluid delivery systems and related components.

Ichor's ongoing manufacturing footprint realignment is expected to have supported gross margin improvement in the third quarter of 2026. The company has qualified additional manufacturing operations in Malaysia, including machining and welding, for its major customers. These initiatives are expected to have increased internal production, reduced reliance on external suppliers and improved product margins. Management expects gross margin to increase by another 100 basis points in each of the remaining two quarters of 2026, with third-quarter gross margin guided to 14.5%-15.5%.

The company is also making progress in expanding its proprietary Ichor-branded content within the systems it builds. After ending the second quarter at around 25%, management expects proprietary content to reach approximately 30% by the end of the third quarter and 35% by the end of 2026. Increasing proprietary content is expected to have supported better product margins and contributed to the company's margin improvement plans.

What Our Model Says About ICHROur proven model does not conclusively predict an earnings beat for ICHR this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. However, that’s not the case here.

ICHR has an Earnings ESP of -0.55% and carries a Zacks Rank #3 at present. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Stocks With Favorable CombinationHere are some stocks worth considering, as our model shows that these have the right combination of elements to beat on earnings this reporting cycle.

AMETEK (AME - Free Report) has an Earnings ESP of +0.37% and sports a Zacks Rank #1 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

AMETEK is slated to report third-quarter 2026 results on Nov. 3. The Zacks Consensus Estimate for AMETEK’s third-quarter 2026 earnings is pegged at $2.12 per share, up by a penny over the past 30 days, indicating a rise of 12.2% from the year-ago quarter’s reported figure.

Shopify (SHOP - Free Report) has an Earnings ESP of +10.11% and sports a Zacks Rank #1 at present.

Shopify is set to report third-quarter 2026 results on Dec. 3. The Zacks Consensus Estimate for Shopify’s third-quarter 2026 earnings is pegged at 45 cents per share, up by a penny over the past 30 days, indicating a rise of 32.4% from the year-ago quarter’s reported figure.

Microchip Technology (MCHP - Free Report) has an Earnings ESP of +1.56% and carries a Zacks Rank #2 at present.

Microchip Technology is set to report second-quarter fiscal 2027 results on Nov. 5. The Zacks Consensus Estimate for Microchip Technology’s second-quarter fiscal 2027 earnings is pegged at 94 cents per share, up by a penny over the past 30 days, indicating a rise of 168.6% from the year-ago quarter’s reported figure.

Key Takeaways Bausch Health's Q3 adjusted EPS surged 52.6% to $1.77, beating estimates on strong Salix performance.Salix revenues rose 16% to $831 million, while organic revenue growth reached 8% company-wide.Bausch Health raised 2026 revenue and EBITDA guidance and authorized a $50 million share repurchase program.
Bausch Health Companies (BHC - Free Report) reported third-quarter 2026 adjusted earnings of $1.77 per share, which increased 52.6% year over year. The figure surpassed the Zacks Consensus Estimate of $1.08, aided by strength in the Salix business.

Revenues rose 9.7% year over year to $2.94 billion and beat the Zacks Consensus Estimate of $2.75 billion. Organic revenues rose 8%, driven by Xifaxan-led Salix growth. The stock is up about 9% in the pre-market hours today following the better-than-expected third-quarter results.

The company reports revenues under two segments: Bausch Health and Bausch + Lomb.

Bausch Health’s revenues amounted to $1.57 billion, up 12% year over year. Within the Bausch Health segment, revenues are recorded under four divisions — Salix, International, Solta Medical and Diversified Products.

Bausch Health's Salix MomentumSalix revenues reached $831 million, up 16% year over year on a reported basis and 14% organically. Xifaxan was the primary growth driver, with sales advancing 16% in the quarter.

Shares of BHC have lost 0.5% year to date against the industry’s 10.2% growth.

Image Source: Zacks Investment Research

The segment exceeded the Zacks Consensus Estimate of $710.52 million and our model estimate of $761.4 million. Overall, Bausch Health's businesses excluding Bausch + Lomb generated $1.57 billion in revenues, up 12% from a year earlier.

BHC's International and Solta ResultsInternational revenues rose 5% to $299 million, with organic growth of 4%, led by Canada. Favorable foreign exchange contributed $4 million. The figure beat the Zacks Consensus Estimate of $286.17 million and our model estimate of $263.8 million.

Solta Medical revenues grew 18% to $165 million, aided by the acquisition of the company's full-service distributor in China. The segment missed the Zacks Consensus Estimate of $169.11 million but exceeded our model estimate of $163.2 million.

Excluding acquisition and currency effects, Solta revenues declined 4% organically, as sales in the Asia-Pacific region decreased modestly.

Bausch Health's Diversified Segment PerformanceDiversified segment revenues increased 5% to $271 million, with organic growth also at 5%. The figure surpassed the Zacks Consensus Estimate of $200.72 million and our model estimate of $179.6 million. Double-digit growth in Dermatology drove the organic increase.

Dermatology revenues climbed 16% to $86 million. Neuroscience revenues were unchanged at $146 million, while Generics rose 13% to $18 million. Dentistry sales declined 5% to $21 million.

BHC's Bausch + Lomb PerformanceBausch + Lomb revenues grew 7% to $1.375 billion, with organic revenues also up 7%. The figure was slightly below the Zacks Consensus Estimate of $1.38 billion and matched our model estimate.

Revenue gains were broad-based. Vision Care sales rose 5% to $774 million, Surgical revenues increased 9% to $234 million, and Pharmaceuticals revenues advanced 11% to $367 million.

Bausch Health's Q3 Margin and Cost TrendsIn the third quarter, BHC’s adjusted gross margin expanded to 75% from 72.7% a year ago. Adjusted cost of goods sold, excluding amortization and impairments of intangible assets, increased slightly to $721 million from $716 million.

Adjusted selling, general and administrative expenses rose 5.9% year over year to $823 million from $777 million, while research and development expenses declined 15.1% to $141 million from $166 million.

Operating income increased 58.8% to $983 million, helped by lower other expenses. Adjusted EBITDA attributable to Bausch Health climbed 32.4% to $1.31 billion.

BHC Raises 2026 Financial GuidanceBHC raised its 2026 consolidated revenue guidance to $10.975-$11.175 billion from $10.79-$11.04 billion. It also increased its adjusted EBITDA projection to $4.315-$4.415 billion from the previous $4.05-$4.18 billion.

Excluding Bausch + Lomb, the company now expects revenues to be in the band of $5.525-$5.625 billion, suggesting growth of 7-9%. Adjusted EBITDA for these businesses is projected to be in the range of $3.225-$3.275 billion, indicating an increase of 12-14% year over year.

For Bausch + Lomb, 2026 revenues are forecast at $5.45-$5.55 billion and adjusted EBITDA at $1.09-$1.14 billion.

Bausch Health's Recent UpdatesThe company's board authorized a $50 million share repurchase program. The primary objective is to offset dilution from management equity awards expected to vest in 2027.

Management continues to evaluate options to unlock shareholder value, including maximizing the value of Bausch Health and Bausch + Lomb assets. The businesses excluding Bausch + Lomb have now delivered 14 consecutive quarters of year-over-year revenue and adjusted EBITDA growth.

Our Take on BHC's Q3 PerformanceBHC delivered solid third-quarter results, benefiting from Xifaxan-led Salix momentum and broad-based growth in its eye-health business. Improved profitability supported another increase in full-year financial guidance.

However, Solta Medical's organic contraction contrasted with its reported revenue gains. Bausch + Lomb also came in marginally below consensus expectations, while higher selling and administrative costs remain an area to watch.

BHC’s Zacks Rank and Other Stocks to ConsiderBausch currently carries a Zacks Rank #2 (Buy).

Some other top-ranked stocks in the biotech sector are TG Therapeutics (TGTX - Free Report) , currently sporting a Zacks Rank #1 (Strong Buy) and Amneal Pharmaceuticals (AMRX - Free Report) and Iovance Biotherapeutics (IOVA - Free Report) , each carrying a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 30 days, earnings per share estimates for TG Therapeutics have risen from 92 cents to 94 cents for 2026. Over the same period, estimates for 2027 earnings per share have increased from $2.65 to $2.66. TGTX’s shares have risen 92.6% year to date.

TG Therapeutics’ earnings missed estimates in three of the trailing four quarters and beat in the remaining one, with the average surprise being 184.65%.

Over the past 30 days, earnings per share estimates for Amneal Pharmaceuticals have increased from $1.03 to $1.04 for 2026. Over the same period, estimates for 2027 earnings per share have risen from $1.16 to $1.19. AMRX’s shares have surged 67.8% year to date.

Amneal Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, delivering the average surprise being 32.82%.

Over the past 30 days, loss per share estimates for Iovance Biotherapeutics have narrowed from 49 cents to 45 cents for 2026. Over the same period, estimates for loss per share have also improved from 29 cents to 22 cents for 2027. IOVA shares have skyrocketed 442.5% year to date.

Iovance Biotherapeutics beat estimates in three of the trailing four quarters and met in the remaining one, with the average surprise being 16.82%.

Pagaya Technologies Ltd. (PGY) came out with quarterly earnings of $1.07 per share, beating the Zacks Consensus Estimate of $0.96 per share.

In 2024, Siemens Energy (SMERY +3.04%)(SMEGF +4.05%) was losing billions of dollars in its wind business. It had to sell non-core assets to free up cash. One of them was Trench Group, a company specializing in high-voltage grid components. The price was undisclosed.

Now, GE Vernova (GEV +3.13%) has agreed to buy that same company from investment firm Triton Partners for a whopping $9 billion.

That one fact tells you almost everything about the artificial intelligence (AI) power business today. What it still doesn't reveal is the scale and pace of GE Vernova's growth.

Image source: Getty Images.

Big acquisition, bigger backlogGE Vernova is the world leader in natural gas and wind turbines. Nearly 25% of all the electricity generated globally passes through its equipment.

It just posted third-quarter numbers, and they're staggering. Orders jumped 96% organically, and backlog grew by $20 billion in a single quarter to reach $197 billion. Management now expects backlog to surpass $200 billion in Q4. That's more than five times the company's 2025 revenue.

Simultaneously, management announced a $9 billion deal to acquire Trench. GE Vernova will pay half in cash and half in debt, and it expects the deal to close in late 2027.

The Trench deal is a masterstrokeGE Vernova operates three businesses:

Power: gas and steam turbines, nuclear and hydro powerElectrification: grid solutions, power conversion, high-voltage equipmentWind: onshore and offshore wind turbines.Power is the largest segment, but electrification is the fastest-growing. It generated roughly 32% of the company's total revenue in the nine months through Sept. 30, 2026, but logged 59% revenue growth.

AI data centers require a massive, constant power supply that traditional grids weren't built to handle. GE Vernova sells the high-voltage transformers, switchgear, and control systems needed to plug these facilities directly into the high-voltage transmission lines.

Supply is so scarce that industry lead times for equipment like transformers now stretch into years. Securing key components is a battleground, so GE Vernova is pulling off a masterstroke: buying the supplier itself.

$905.48+$27.45 (+3.13%)

NYSE · As of 11:30 AM ET 10/29/26

Trench makes bushings, instrument transformers, and coils, or the kind of parts that go into transformers and other equipment. It serves more than 800 utilities and hyperscalers worldwide, has manufacturing facilities across North America, Europe, and Asia, and brings a backlog of nearly $5 billion.

It is already a GE Vernova supplier, and supplies to Siemens Energy and Hitachi's (HTHIY -10.94%) arm, Hitachi Energy, too. So by acquiring Trench, GE Vernova locks up its own supply chain while seizing control of a major bottleneck for two of its biggest grid rivals.

It's a clear strategy: own the AI build-out bottleneck.

What this means for GE Vernova investorsGE Vernova raised its full-year targets for sales, profit margins, and cash flows. It exited Q3 with $16.8 billion in cash and generated $5.4 billion in free cash flow, up from only $732 million a year ago. Customers are paying cash upfront to reserve turbine slots years in advance.

All of that money gives the company significant leeway to spend on growth and return cash to shareholders. Earlier this year, it bought the remaining stake in transformer maker Prolec GE. It is now buying Trench, and management just doubled its stock buyback plan to $20 billion.

GE Vernova's backlog gives it multi-year revenue visibility few industrial companies can match. The stock's still down nearly 17% in six months, as of this writing. This is one company the market isn’t pricing right.

Key Takeaways Garmin raises its 2026 revenue outlook to $8.15 billion and earnings guidance to $10.80 per share.Strong wearables demand drives 16% fitness growth and 20% outdoor growth, supporting Garmin's Q3 results.Rising memory costs threaten 2027 margins, while Garmin expects a Mercedes-Benz program to lift auto sales.
During the third-quarter 2026 earnings call, Garmin Ltd. (GRMN - Free Report) raised its full-year outlook following record quarterly operating results, supported by strong wearable demand, favorable product mix and improved profitability. Management emphasized continued momentum heading into the holiday season.

However, the earnings call also highlighted rising memory costs, supply constraints and potential margin normalization in 2027, even as the company expands production capacity and prepares for new automotive programs.

GRMN reported third-quarter earnings of $2.76 per share, exceeding the Zacks Consensus Estimate of $2.38. Revenues of $1.99 billion matched the rounded consensus estimate.

GRMN Raises 2026 Outlook on Strong ExecutionPresident and CEO Clifton Pemble said Garmin expects 2026 revenues of approximately $8.15 billion, up $100 million from its previous forecast. Pro forma earnings guidance increased 80 cents to $10.80 per share.

CFO and Treasurer Douglas Boessen outlined updated gross and operating margin expectations of 61% and 29%, respectively. The effective tax rate forecast remained unchanged at 16.5%.

Garmin Faces Rising Memory Costs in 2027Pemble cautioned that significantly higher memory and raw material prices will increasingly affect profitability as previously purchased lower-cost inventory is consumed.

During the analyst discussion, Barclays questioned the sustainability of elevated margins. Boessen explained that favorable segment mix, Taiwan dollar weakness and $33 million in tariff refunds supported third-quarter profitability.

Management expects gross margins to return toward historical levels in 2027. Pemble emphasized vertical integration, manufacturing scale and selective pricing measures as potential tools for mitigating cost pressures.

GRMN Sees Sustained Wearables DemandFitness revenues increased 16% to $694 million, driven by wearables. Pemble highlighted stronger-than-expected initial demand for the CIRQA Smart Band, with production efforts focused on fulfilling outstanding orders.

Outdoor revenues climbed 20% to $597 million, supported by the newly introduced fenix 9 series. Management expects demand for adventure watches to sustain fourth-quarter growth.

During JPMorgan's questioning, Pemble noted that product registrations exceeded channel sell-in, indicating strong consumer demand despite some retailer destocking. He also said Garmin Connect Plus subscriptions exceeded management expectations, with encouraging renewal trends.

Garmin Highlights Marine and Aviation OpportunitiesMarine revenues advanced 16% to $310 million, supported by sonar products, particularly LiveScope 2. The segment benefited from tariff refunds, underlying margins also improved.

Responding to KeyBanc, Pemble acknowledged softness in the broader marine market, partly reflecting elevated fuel prices. However, demand for newer midrange boats and equipment retrofits remained encouraging.

Aviation revenues increased 5% to $253 million. Management highlighted more than 2,500 aircraft equipped with Garmin Autoland and continued expansion of its flight deck technology across original equipment and retrofit markets.

GRMN Prepares for Automotive RecoveryAuto OEM revenues declined 20% to $132 million as domain controller sales weakened. However, the segment's operating loss narrowed to $12 million following the reassignment of research and development resources.

Pemble expects another comparable revenue decline in the fourth quarter before a major Mercedes-Benz domain controller program supports significant growth in 2027.

During questioning from Tigress Financial Partners, Pemble indicated that the Mercedes-Benz program should begin ramping earlier rather than later in 2027, although precise timing depends on customer production schedules.

Garmin Balances Inventory and Cash FlowBoessen reported third-quarter free cash flow of $293 million, down $132 million year over year, primarily reflecting higher inventory and supplier prepayments.

Management now expects approximately $1.1 billion in full-year free cash flow and $500 million in capital expenditures. Inventory reached approximately $2.3 billion as Garmin secured critical components.

Pemble also confirmed that its Thailand manufacturing facility remains on schedule to begin production in the first quarter of 2027, providing additional capacity amid growing volumes.

GRMN Maintains Focus on ExecutionManagement's tone remained confident about near-term demand while acknowledging supply-chain pressures and uncertainty surrounding 2027 profitability.

Garmin continues prioritizing product innovation, manufacturing expansion and component availability, with fourth-quarter execution and rising input costs central to its outlook.

Garmin's Zacks Rank and Style Scores SignalGarmin currently carries a Zacks Rank #3 (Hold), indicating a neutral near-term earnings-revision outlook. Its Growth Score of B and Momentum Score of B reflect relatively favorable growth and price momentum characteristics. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

However, its Value Score of D indicates less attractive valuation characteristics, while the VGM Score of C reflects a mixed overall profile. These scores provide additional context alongside the Zacks Rank rather than definitive signals of future returns. Investors should note that the Zacks Rank may change as analysts revise earnings estimates following the latest quarterly results.

, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against D-Wave Quantum Inc. ("D-Wave" or the "Company") (NASDAQ:QBTS) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 26-cv-12155, is on behalf of a class consisting of all persons and entities other than the above-captioned defendants ("Defendants") that purchased or otherwise acquired D-Wave securities between February 27, 2026 and August 25, 2026, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are an investor who purchased or otherwise acquired D-Wave securities during the Class Period, you have until December 15, 2026 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

[Click here for information about joining the class action]

D-Wave is a quantum computing company focused on the development and delivery of quantum computing systems, software, and services.

At all relevant times, D-Wave represented that its "business model is focused on generating revenue from providing customers access to our quantum computing systems via the cloud in the form of quantum computing as a service products, providing professional services wherein we assist our customers in identifying and implementing quantum computing applications, and selling our quantum computer systems to customers." Accordingly, Defendants reported the Company's revenue in segments including, as relevant here, quantum computer system sales.

After entering into an agreement to sell a quantum computer system, D-Wave recognizes revenue from such sales on a percentage of completion basis, given that several steps are required to render a quantum computer system operational, including but not limited to preparation of the site where the quantum computer will be located, installation, and subsequent calibration of the system.

Although Defendants disclosed to investors these intermediary steps that D-Wave would need to complete between entering a quantum computer sales agreement and recognizing revenue from that sale, they nonetheless assured investors that revenue recognition from such system sales would take place within "multiple months and possibly quarters".

On January 27, 2026, D-Wave announced that Florida Atlantic University had agreed to purchase a quantum computer system for $20 million (the "FAU System Sale"). In this announcement, D-Wave stated that the "deployment" of this quantum computer system was "expected later in 2026". Given that D-Wave, at all relevant times, recognized revenue from quantum computer systems sales on a percentage-of-completion basis, stating that D-Wave expected deployment of a quantum computer system later in 2026 was, in essence, a statement that Defendants expected D-Wave to recognize revenue from the sale of this system later in 2026.

In addition, throughout the Class Period Defendants consistently assured investors that D-Wave enjoyed robust bookings for future sales and that D-Wave's customers expressed "growing interest" in such sales.

The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Defendants materially understated the amount of time needed to execute intermediary steps necessary to recognize revenue from quantum computer system sales, including the FAU System Sale; (ii) Defendants materially overstated their ability to convert purportedly robust demand for quantum computer systems into sales agreements and recognized revenue; and (iii) as a result, Defendants' public statements were materially false and misleading at all relevant times.

The truth began to emerge on May 12, 2026, when D-Wave reported its financial results for the first quarter of 2026. Among other items, D-Wave reported revenue of only $2.86 million, compared to $12.6 million for the same period in the prior year, and below analyst expectations of $4.04 million. D-Wave also announced a revised timetable concerning FAU's quantum computer system, stating that "system installation is expected to commence before the end of 2026".

On this news, D-Wave's stock price fell $1.68 per share, or 6.69%, to close at $22.35 per share on May 12, 2026.

Then, on August 6, 2026, D-Wave reported its financial results for the second quarter of 2026. Among other items, D-Wave reported revenue of only $3.08 million, compared to $3.1 million for the same period in the prior year, and missed analyst expectations in the range of $4.03 million to $4.08 million. In the quarterly report on Form 10-Q it filed with the United States Securities and Exchange Commission ("SEC") that day, D-Wave explained its revenue from system sales during the quarter decreased year-over-year by $0.8 million, "primarily due to variability in the timing and extent of system installation activities and extent of installation activities in each period", and similarly attributed a year-over year decrease in its revenue for the first six months of 2026 to a "decrease in systems sales" that "was primarily due to the timing of progress recognized under the percentage-of-completion method on the system contracted for delivery in each period."

On this news, D-Wave's stock price fell $1.99 per share, or 9.28%, to close at $19.41 per share on August 6, 2026.

Then, on August 25, 2026, D-Wave issued a press release "announc[ing] that John Markovich is retiring and thus resigning from his position as Chief Financial Officer effective September 2, 2026."

On this news, D-Wave's stock price fell $1.84 per share, or 9.51%, to close at $17.51 per share on August 26, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Danielle Peyton

Pomerantz LLP

[email protected]

646-581-9980 ext. 7980

SOURCE Pomerantz LLP

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In D-Wave Quantum To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in D-Wave Quantum between February 26, 2026 and August 25, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - October 29, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against D-Wave Quantum Inc. ("D-Wave Quantum" or the "Company") (NASDAQ: QBTS) and reminds investors of the December 15, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Defendants materially overstated D-Wave's business and financial prospects; (ii) the foregoing was reasonably likely to negatively impact the Company's business and reputation; and (iii) as a result, Defendants' public statements were materially false and misleading at all relevant times.

On August 6, 2026, D-Wave announced its financial results for the second quarter of 2026, reporting revenue of just $3.08 million, compared to $3.1 million for the same period in the prior year, falling short of analyst expectations ranging from $4.03 million to $4.08 million. On this news, D-Wave's stock price declined $1.99 per share, or 9.28%, to close at $19.41 per share on August 6, 2026.

On August 25, 2026, D-Wave issued a press release "announc[ing] that John Markovich is retiring and thus resigning from his position as Chief Financial Officer effective September 2, 2026." On this news, D-Wave's stock price fell $1.84 per share, or 9.51%, closing at $17.51 per share on August 26, 2026.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding D-Wave Quantum's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the D-Wave Quantum class action, go to www.faruqilaw.com/QBTS or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Frequently Asked Questions (FAQ) for Investors Regarding the D-Wave Quantum Securities Class Action Lawsuit:

What is the D-Wave Quantum securities fraud lawsuit about?

The lawsuit alleges that D-Wave Quantum Inc. and certain of its officers and directors made materially false and misleading statements and/or failed to disclose material information during the Class Period. Specifically, the complaint alleges that Defendants materially overstated D-Wave's business and financial prospects, and that this alleged misrepresentation was reasonably likely to negatively impact the Company's business and reputation. As a result, the lawsuit alleges that Defendants' public statements were materially false and misleading at all relevant times during the Class Period. The action was filed on behalf of investors who suffered damages as a result of their reliance on those allegedly false and misleading statements.

Who may be eligible to participate in the lawsuit?

Investors who purchased or otherwise acquired D-Wave Quantum Inc. (NASDAQ: QBTS) securities between February 26, 2026 and August 25, 2026, inclusive, may be eligible to participate in this lawsuit. Eligibility is not limited to those who seek appointment as lead plaintiff; any class member who suffered losses during the Class Period may potentially share in any recovery obtained. Investors are encouraged to review their trading records for the relevant period to assess whether they purchased QBTS securities during the Class Period. Faruqi & Faruqi, LLP invites potentially affected investors to contact the firm to discuss their legal rights and options.

What is a lead plaintiff, and how can I seek appointment?

A lead plaintiff is a court-appointed representative who acts on behalf of all class members and plays an active role in directing the litigation, including working with counsel to make key strategic decisions in the case. Any investor who purchased D-Wave Quantum securities during the Class Period and suffered a loss may move the court for appointment as lead plaintiff by the applicable lead plaintiff deadline. Courts typically appoint the movant with the largest financial interest in the relief sought, provided that movant satisfies the relevant legal requirements. Importantly, investors need not serve as lead plaintiff to share in any recovery that may be obtained; class members who do not seek appointment may still participate in any settlement or judgment.

Why should investors contact Faruqi & Faruqi, LLP?

Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased D-Wave Quantum securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/321421

Source: Faruqi & Faruqi LLP

Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Smurfit Westrock's Q3 revenue increased 2%, but higher production and freight costs pushed adjusted EBITDA down 7.5% and reduced margins by 150 basis points. Management lowered its FY2026 EBITDA guidance to $4.7 billion, prompting us to cut our earnings forecast by 6%. North American capacity closures, planned containerboard price increases and WestRock integration savings could support a stronger earnings recovery in 2027.

IRVINE, Calif.--(BUSINESS WIRE)--The fun discoveries continue at Kura Revolving Sushi Bar, as Yoshi, Mr. E, and Smiley Flowers leap from the pages of the storybook and into the iconic Bikkura Pon prize machine! Kura Sushi USA, Inc., the nation's largest brand of revolving sushi restaurants, today announced its partnership with Nintendo of America to bridge the world of the Yoshi and the Mysterious Book game on the Nintendo Switch 2 system with Kura Sushi's playful dining experience.Starting Nov.

29.10.2026 16:32

Pražská burza po jednodenní přestávce způsobené státním svátkem zakončila obchodování v kladných hodnotách. Index PX si nakonec polepšil o 0,38 % na 2 648 bodů. Nejvýraznější růst zaznamenaly akcie zbrojovky CSG, které posílily o 5,45 % na 361 Kč. Emise Colt CZ si připsala 1,19 % na 850 Kč. Dařilo se rovněž rakouským finančním titulům. Erste Bank vzrostla o 1,32 % na 2 618 Kč a pojišťovna VIG posílila o 0,81 % na 1 734 Kč. Moneta Money Bank si polepšila o 1,19 % nad 196 Kč. Naopak ČEZ korigoval úterní nárůst a oslabil o 1,58 % na 1 368 Kč. Akcie Doosan Škoda Power odepsaly 2,78 % na 397 Kč v reakci na zprávu, že korejská společnost KHNP nedosáhla dohody s konsorciem jihokorejských firem ohledně smluvních podmínek stavebních prací na nových jaderných blocích v Dukovanech. Komerční banka po dnešním zveřejnění hospodářských výsledků mírně oslabila o 0,30 % na 1 004 Kč.

Josef Dudek, makléř, Fio banka, a.s.

Mach Natural Resources LP (MNR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wall Street expects a year-over-year increase in earnings on higher revenues when GigaCloud Technology Inc. (GCT - Free Report) reports results for the quarter ended September 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.

The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.

While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.

Zacks Consensus EstimateThis company is expected to post quarterly earnings of $1.28 per share in its upcoming report, which represents a year-over-year change of +29.3%.

Revenues are expected to be $394.8 million, up 18.7% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 20% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for GigaCloud Technology Inc.?For GigaCloud Technology Inc., the Most Accurate Estimate is the same as the Zacks Consensus Estimate, suggesting that there are no recent analyst views which differ from what have been considered to derive the consensus estimate. This has resulted in an Earnings ESP of 0%.

On the other hand, the stock currently carries a Zacks Rank of #1.

So, this combination makes it difficult to conclusively predict that GigaCloud Technology Inc. will beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that GigaCloud Technology Inc. would post earnings of $0.85 per share when it actually produced earnings of $1.16, delivering a surprise of +36.47%.

Over the last four quarters, the company has beaten consensus EPS estimates four times.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

GigaCloud Technology Inc. doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

An Industry Player's Expected ResultsAnother stock from the Zacks Technology Services industry, AppLovin (APP - Free Report) , is soon expected to post earnings of $3.95 per share for the quarter ended September 2026. This estimate indicates a year-over-year change of +61.2%. Revenues for the quarter are expected to be $2.08 billion, up 47.8% from the year-ago quarter.

The consensus EPS estimate for AppLovin has been revised 1.2% lower over the last 30 days to the current level. However, a higher Most Accurate Estimate has resulted in an Earnings ESP of +3.04%.

When combined with a Zacks Rank of #4 (Sell), this Earnings ESP makes it difficult to conclusively predict that AppLovin will beat the consensus EPS estimate. The company beat consensus EPS estimates in each of the trailing four quarters.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.